These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 36298443)
1. Outer Membrane Vesicles: An Emerging Vaccine Platform. Kashyap D; Panda M; Baral B; Varshney N; R S; Bhandari V; Parmar HS; Prasad A; Jha HC Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298443 [TBL] [Abstract][Full Text] [Related]
2. Bioengineering bacterial outer membrane vesicles as vaccine platform. Gerritzen MJH; Martens DE; Wijffels RH; van der Pol L; Stork M Biotechnol Adv; 2017 Sep; 35(5):565-574. PubMed ID: 28522212 [TBL] [Abstract][Full Text] [Related]
3. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8 Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032 [TBL] [Abstract][Full Text] [Related]
4. Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants. Tan K; Li R; Huang X; Liu Q Front Microbiol; 2018; 9():783. PubMed ID: 29755431 [TBL] [Abstract][Full Text] [Related]
5. Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. Rollier CS; Dold C; Marsay L; Linder A; Green CA; Sadarangani M; Norheim G; Derrick JP; Feavers IM; Maiden MCJ; Pollard AJ mSphere; 2022 Feb; 7(1):e0067421. PubMed ID: 35080470 [TBL] [Abstract][Full Text] [Related]
6. Designer outer membrane vesicles as immunomodulatory systems - Reprogramming bacteria for vaccine delivery. Gnopo YMD; Watkins HC; Stevenson TC; DeLisa MP; Putnam D Adv Drug Deliv Rev; 2017 May; 114():132-142. PubMed ID: 28501509 [TBL] [Abstract][Full Text] [Related]
7. A "Plug-and-Display" Nanoparticle Vaccine Platform Based on Outer Membrane Vesicles Displaying SARS-CoV-2 Receptor-binding Domain. Feng R; Li GC; Jing HM; Liu C; Xue RY; Zou QM; Li HB J Vis Exp; 2022 Jul; (185):. PubMed ID: 35938846 [TBL] [Abstract][Full Text] [Related]
8. Bacterial-Derived Outer Membrane Vesicles are Potent Adjuvants that Drive Humoral and Cellular Immune Responses. Prior JT; Davitt C; Kurtz J; Gellings P; McLachlan JB; Morici LA Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33498352 [TBL] [Abstract][Full Text] [Related]
10. Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Gerritzen MJH; Salverda MLM; Martens DE; Wijffels RH; Stork M Vaccine; 2019 Nov; 37(47):6978-6986. PubMed ID: 31383485 [TBL] [Abstract][Full Text] [Related]
11. Engineered bacterial outer membrane vesicles: a versatile bacteria-based weapon against gastrointestinal tumors. Zheng K; Feng Y; Li L; Kong F; Gao J; Kong X Theranostics; 2024; 14(2):761-787. PubMed ID: 38169585 [TBL] [Abstract][Full Text] [Related]
12. Bacterial outer membrane vesicles as a candidate tumor vaccine platform. Wang S; Guo J; Bai Y; Sun C; Wu Y; Liu Z; Liu X; Wang Y; Wang Z; Zhang Y; Hao H Front Immunol; 2022; 13():987419. PubMed ID: 36159867 [TBL] [Abstract][Full Text] [Related]
13. Bacterial outer membrane vesicle-based cancer nanovaccines. Gao X; Feng Q; Wang J; Zhao X Cancer Biol Med; 2022 Sep; 19(9):1290-300. PubMed ID: 36172794 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Sanders H; Feavers IM Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]